Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study
- 5 April 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 9 (2), 159-165
- https://doi.org/10.1093/jpids/piy139
Abstract
P1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy outcomes for the oldest cohort. The study enrolled human immunodeficiency virus type 1 (HIV-1)–infected treatment-experienced adolescents aged 12 to <18 years, with an HIV-1 RNA level ≥1000 copies/mL . Cumulative safety and HIV-1 RNA outcomes were assessed once the last enrolled participant reached 144 weeks of follow-up. Among 23 adolescents enrolled, 16 remained in the study at least 144 weeks; the median follow-up was 153 weeks (range, 55–193 weeks). Dolutegravir was well tolerated, with grade 3 clinical adverse events in 5 participants, grade 3 laboratory abnormalities in 3, and grade 4 laboratory abnormalities in 1; none of the adverse events or abnormalities were judged to be treatment related. In an-intent-to-treat analysis, an HIV-1 RNA level <400 copies/mL at week 144 was achieved in 43% (10 of 23 participants; 95% confidence interval, 23.2%–65.5%); in addition, 35% (8 of 23; 16.4%–57.3%) had an HIV-1 RNA level <50 copies/mL. Nine participants (39%) discontinued study treatment before 144 weeks, but none because of adverse events or drug intolerance. All participants with sustained virologic control had excellent adherence; most who experienced virologic failure had adherence levels <90%. HIV-1 genotypic drug resistance testing was available at time of failure from 6 participants; 1 had evolution in integrase resistance with E138T, S147G, and R263K mutations at week 192 and phenotypic dolutegravir resistance of a 5.1-fold change. Dolutegravir plus an optimized background regimen seemed safe, well tolerated, and efficacious in this cohort of treatment-experienced HIV-1-infected adolescents. Adherence remains problematic in this population. NCT01302847.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (UM1AI068632, UM1AI068616, UM1AI106716)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Mental Health
- ViiV Healthcare
This publication has 20 references indexed in Scilit:
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionThe New England Journal of Medicine, 2013
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialThe Lancet Infectious Diseases, 2013
- Effect of HIV genotypic drug resistance testing on the management and clinical course of HIV-infected children and adolescentsInternational Journal of STD & AIDS, 2013
- Trends in Hospitalizations of HIV-Infected Children and Adolescents in the United States: Analysis of Data From the 1994–2003 Nationwide Inpatient SamplePEDIATRICS, 2007
- Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected childrenJournal of Medical Virology, 2007
- Clinical Outcomes Improve with Highly Active Antiretroviral Therapy in Vertically HIV Type‐1–Infected ChildrenClinical Infectious Diseases, 2006
- Decrease in Hospitalization and Mortality Rates among Children with Perinatally Acquired HIV Type 1 Infection Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2004
- Starting highly active antiretroviral therapy: why, when and response to HAARTJournal of Antimicrobial Chemotherapy, 2004
- Decline in the AIDS and death rates in the EuroSIDA study: an observational studyThe Lancet, 2003
- Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1The New England Journal of Medicine, 2001